Abbott Laboratories announced on March 23 2026 that it has closed a $21 billion equity acquisition of Exact Sciences, a leading provider of cancer screening and precision‑oncology diagnostics. The deal values Exact Sciences at $105 per share, giving Abbott a fully owned subsidiary that adds high‑margin products such as the Cologuard colorectal cancer test, the Oncotype DX breast‑cancer assay, and the multi‑cancer early‑detection blood test Cancerguard. The transaction expands Abbott’s diagnostics footprint into a U.S. market estimated at $60 billion and positions the company to offer a comprehensive suite of early‑detection tools across multiple cancer types.
Exact Sciences reported $878 million in revenue and a net loss of $86 million in its fourth quarter of 2025, while its full‑year 2025 revenue reached $3.25 billion with a net loss of $207.9 million. The company’s screening and precision‑oncology segments drove the revenue growth, but continued losses reflect the high cost of research, development, and regulatory compliance that are typical for a growth‑stage diagnostics firm. Abbott’s acquisition of Exact Sciences therefore brings a proven product portfolio and a strong growth trajectory into its own commercial and manufacturing network.
Abbott’s own fourth‑quarter 2025 results showed revenue of $11.46 billion, slightly below analyst expectations, while adjusted earnings per share of $1.50 met consensus estimates. The revenue miss was largely attributed to a decline in demand for COVID‑19 testing, which had been a significant contributor to Abbott’s diagnostics revenue in previous years. The company’s medical‑device segment, however, delivered double‑digit growth, offsetting the weakness in its nutrition and diagnostics businesses. The acquisition is intended to diversify Abbott’s revenue base and accelerate the adoption of its new precision‑oncology tests in both clinical and population‑based screening settings.
Strategically, the deal allows Abbott to move beyond the declining COVID‑19 testing market and to capture a share of the rapidly expanding cancer diagnostics arena. By integrating Exact Sciences’ assays into Abbott’s existing diagnostics platform, the company can leverage its global manufacturing and commercial network to scale the distribution of high‑margin tests. The $60 billion U.S. market for cancer screening and precision oncology diagnostics offers a tailwind for Abbott, and the acquisition is expected to add approximately $3 billion in incremental sales in 2026. The transaction also strengthens Abbott’s competitive stance against other diagnostics leaders such as Thermo Fisher and Roche, while providing a broader product mix beyond its traditional medical‑device and nutrition businesses.
Analysts have expressed mixed views on the transaction. UBS reiterated a “Buy” rating for Abbott and maintained a $158 price target, noting that the deal could add about 300 basis points to Abbott’s diagnostics‑segment growth. Stifel’s Rick Wise highlighted potential for international growth and innovation, while Mizuho downgraded Exact Sciences from “Outperform” to “Neutral” after the announcement, reflecting concerns about the premium paid. Overall, the market reaction was tempered by valuation concerns, but the strategic benefits of entering the high‑growth cancer diagnostics market were widely acknowledged.
The acquisition positions Abbott to accelerate its long‑term growth strategy in diagnostics, providing a diversified portfolio that can offset the decline in COVID‑19 testing revenue. By combining Exact Sciences’ high‑margin test portfolio with Abbott’s global commercial reach, the company is poised to capture a larger share of the $60 billion cancer diagnostics market and to deliver incremental revenue and earnings growth in the coming years. The deal also signals Abbott’s commitment to expanding its precision‑oncology capabilities, which could drive future product innovation and market leadership.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.